Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.5.2859

Ellagic Acid Inhibits Migration and Invasion by Prostate Cancer Cell Lines  

Pitchakarn, Pornsiri (Department of Biochemistry, Faculty of Medicine, Chiang Mai University)
Chewonarin, Teera (Department of Biochemistry, Faculty of Medicine, Chiang Mai University)
Ogawa, Kumiko (Department of Experimental Pathology and Tumor Biology, Nagoya City University, Graduate School of Medical Sciences)
Suzuki, Shugo (Department of Experimental Pathology and Tumor Biology, Nagoya City University, Graduate School of Medical Sciences)
Asamoto, Makoto (Department of Experimental Pathology and Tumor Biology, Nagoya City University, Graduate School of Medical Sciences)
Takahashi, Satoru (Department of Experimental Pathology and Tumor Biology, Nagoya City University, Graduate School of Medical Sciences)
Shirai, Tomoyuki (Department of Experimental Pathology and Tumor Biology, Nagoya City University, Graduate School of Medical Sciences)
Limtrakul, Pornngarm (Department of Biochemistry, Faculty of Medicine, Chiang Mai University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.5, 2013 , pp. 2859-2863 More about this Journal
Abstract
Polyphenolic compounds from pomegranate fruit extracts (PFEs) have been reported to possess antiproliferative, pro-apoptotic, anti-inflammatory and anti-invasion effects in prostate and other cancers. However, the mechanisms responsible for the inhibition of cancer invasion remain to be clarified. In the present study, we investigated anti-invasive effects of ellagic acid (EA) in androgen-independent human (PC-3) and rat (PLS10) prostate cancer cell lines in vitro. The results indicated that non-toxic concentrations of EA significantly inhibited the motility and invasion of cells examined in migration and invasion assays. The EA treatment slightly decreased secretion of matrix metalloproteinase (MMP)-2 but not MMP-9 from both cell lines. We further found that EA significantly reduced proteolytic activity of collagenase/gelatinase secreted from the PLS-10 cell line. Collagenase IV activity was also concentration-dependently inhibited by EA. These results demonstrated that EA has an ability to inhibit invasive potential of prostate cancer cells through action on protease activity.
Keywords
Ellagic acid; cancer; invasion; migration; metastasis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Azzam HS, Thompson EW (1992). Collagen-induced activation of the M(r) 72,000 type IV collagenase in normal and malignant human fibroblastoid cells. Cancer Res, 52, 4540-4.
2 Bell C, Hawthorne S (2008). Ellagic acid, pomegranate and prostate cancer -- a mini review. J Pharm Pharmacol, 60, 139-44.   DOI   ScienceOn
3 Bianco FJ Jr, Gervasi DC, Tiguert R, et al (1998). Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clin Cancer Res, 4, 3011-6.
4 Braun-Falco M, Holtmann C, Lordick F, et al (2006). Follicular drug reaction from cetuximab: a common side effect in the treatment of metastatic colon carcinoma. Hautarzt, 57, 701-4.   DOI
5 Castonguay AGHU, Perchellet EM (1997). Antitumorigenic and antipromoting activities of ellagic acid, ellagitannins and oligometric anthocyanin and procyanidin. Int J Oncol, 10, 367-73.
6 Cockett MI, Murphy G, Birch ML, et al (1998). Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp, 63, 295-313.
7 Fernandez-Patron C, Radomski MW, Davidge ST (1999). Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res, 85, 906-11.   DOI   ScienceOn
8 Fidler IJ, Kripke ML (1977). Metastasis results from preexisting variant cells within a malignant tumor. Science, 197, 893-5.   DOI
9 Giancotti FG, Ruoslahti E (1999). Integrin signaling. Science, 285, 1028-32.   DOI   ScienceOn
10 Gilles C, Polette M, Seiki M, et al (1997). Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab Invest, 76, 651-60.
11 Gronberg H (2003). Prostate cancer epidemiology. Lancet, 361, 859-64.   DOI   ScienceOn
12 Hamasaki K, Kogure K, Ohwada K (1996). A biological method for the quantitative measurement of tetrodotoxin (TTX): tissue culture bioassay in combination with a water-soluble tetrazolium salt. Toxicon, 34, 490-5.   DOI   ScienceOn
13 Han DH, Lee MJ, Kim JH (2006). Antioxidant and apoptosisinducing activities of ellagic acid. Anticancer Res, 26, 3601-6.
14 Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics, 2008. CA Cancer J Clin, 58, 71-96.   DOI   ScienceOn
15 Khanduja KL, Avti PK, Kumar S, et al (2006). Anti-apoptotic activity of caffeic acid, ellagic acid and ferulic acid in normal human peripheral blood mononuclear cells: a Bcl-2 independent mechanism. Biochim Biophys Acta, 1760, 283-9.   DOI   ScienceOn
16 Liotta LA, Rao CN, Wewer UM (1986). Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem, 55, 1037-57.   DOI   ScienceOn
17 Lansky EP, Harrison G, Froom P, et al (2005). Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel. Invest New Drugs, 23, 121-2.   DOI   ScienceOn
18 Larrosa M, Tomas-Barberan FA, Espin JC (2006). The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. J Nutr Biochem, 17, 611-25.   DOI   ScienceOn
19 Lin SS, Lai KC, Hsu SC, et al (2009). Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and vascular endothelial growth gactor (VEGF). Cancer Lett, 285, 127-33.   DOI   ScienceOn
20 Li TM, Chen GW, Su CC, et al (2005). Ellagic acid induced p53/p21 expression, G1 arrest and apoptosis in human bladder cancer T24 cells. Anticancer Res, 25, 971-9.
21 Longtin R (2003). The pomegranate: nature's power fruit? J Natl Cancer Inst, 95, 346-8.   DOI   ScienceOn
22 Mukhtar H, Das M, Khan WA, et al (1988). Exceptional activity of tannic acid among naturally occurring plant phenols in protecting against 7,12-dimethylbenz(a) anthracene-, benzo(a)pyrene-, 3-methylcholanthrene-, and N-methyl-N-nitrosourea-induced skin tumorigenesis in mice. Cancer Res, 48, 2361-5.
23 Nagase H, Woessner JF, Jr. (1999). Matrix metalloproteinases. J Biol Chem, 274, 21491-4.   DOI
24 Nakanishi H TS, Kato K, Shimizu S, et al (1996). Establishment and characterization of three androgen-independent, metastatic carcinoma cell lines from 3,2'-dimethyl-4-aminobiphenyl-induced prostatic tumors in F344 rats. Jpn J Cancer Res, 87, 1218-26.   DOI
25 Seeram NP, Adams LS, Henning SM, et al (2005). In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem, 16, 360-7.   DOI   ScienceOn
26 Narayanan BA, Geoffroy O, Willingham MC, et al (1999). p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett, 136, 215-21.   DOI   ScienceOn
27 Papathoma AS, Zoumpourlis V, Balmain A, et al (2001). Role of matrix metalloproteinase-9 in progression of mouse skin carcinogenesis. Mol Carcinog, 31, 74-82.   DOI   ScienceOn
28 Pitchakarn P, Ogawa K, Suzuki S, et al (2010). Momordica charantia leaf extract suppresses rat prostate cancer progression in vitro and in vivo. Cancer Sci, 101, 2234-40.   DOI   ScienceOn
29 Seeram NP, Henning SM, Zhang Y, et al (2006). Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr, 136, 2481-5.
30 Seeram NP, Aronson WJ, Zhang Y, et al (2007). Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem, 55, 7732-7.   DOI   ScienceOn
31 Stetler-Stevenson WG (1990). Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev, 9, 289-303.   DOI   ScienceOn
32 Stoner GD, Gupta A (2001). Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis, 22, 1737-46.   DOI   ScienceOn
33 Strati A, Papoutsi Z, Lianidou E, et al (2009). Effect of ellagic acid on the expression of human telomerase reverse transcriptase (hTERT) alpha+beta+ transcript in estrogen receptor-positive MCF-7 breast cancer cells. Clin Biochem, 42, 1358-62.   DOI   ScienceOn
34 Yodkeeree S, Garbisa S, Limtrakul P (2008). Tetrahydrocurcumin inhibits HT1080 cell migration and invasion via downregulation of MMPs and uPA. Acta Pharmacol Sin, 29, 853-60.   DOI   ScienceOn
35 Thresiamma KC, Kuttan R (1996). Inhibition of liver fibrosis by ellagic acid. Indian J Physiol Pharmacol, 40, 363-6.
36 Wang M, Wang T, Liu S, et al (2003). The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol, 20, 65-72.   DOI   ScienceOn
37 Westermarck J, Kahari VM (1999). Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J, 13, 781-92.
38 Zeng ZS, Cohen AM, Guillem JG (1999). Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis, 20, 749-55.   DOI   ScienceOn